Professor Eleni Aklillu, GH-Pharma research group leader at the Department of Global Public Health, is leading the coordination of the EU MAV+ project in Rwanda. Sweden is part of the Team Europe initiative with a total budget of €10 million, managed by Sida.
Funded by the European Union, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines, and Health Technologies in Africa (EU MAV+ initiative) aims to enhance vaccine biomanufacturing and access to essential health products across Africa. Sweden is part of the Team Europe initiative, managing a total budget of €10 million through Sida.
Three Swedish universities are key partners in the project: Karolinska Institutet (KI), Gothenburg University, and Umeå University, collaborating closely with the University of Rwanda. On behalf of these Swedish institutions, GPH has signed a grant agreement of around 2 million SEK to fund the six-month inception phase of the project.
During this phase, key activities include the preparation of a logical framework and detailed work plan for the next four years of the project. Additional milestones include the development of a PhD program in Medical and Health Sciences and the creation of an MSc curriculum in Clinical Trials. Professor Eleni Aklillu is actively involved in driving the project's implementation.
